SEC Form 4 · accession 0001325812-15-000067
ALNYLAM PHARMACEUTICALS, INC. · ALNY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David-Alexandre C Gros
Officer — SVP, Chief Business Officer
Period of report
Dec 18, 2015
Accepted (ET)
Dec 22, 2015 · 5:08 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001178670
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $88.95 | Dec 18, 2015 | A | 15,012 | A | — | Dec 18, 2025 | Common Stock | 15,012 | 15,012 | D |
Explanation of responses
- F1The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter.